Author Insights: Some Clinical Trials Intended for Drug Marketing, Not Advancing Science « news@JAMA (seeding trials)

What did these pharma marketers think they were going to hear by inviting bioethicist Carl Elliott? - Gary Schwitzer's HealthNewsReview Blog

What did these pharma marketers think they were going to hear by inviting bioethicist Carl Elliott?

By Gary Schwitzer on April 12, 2011 2:50 PM 
 

The DTC (direct to consumer) National Conference ("The Forum for DTC Thought Leaders") invited tough-talking, straight-shooting bioethicist Carl Elliott to speak this year.


Then, at least according to this account, some didn't like "the feeling" that he imparted.


Scroll down to "Day One - Afternoon." If you didn't want to hear that "everything is broken - our government, our healthcare system, and the clinical trials side of the industry," then maybe Elliott was not the guy to invite.


Health care journalists who haven't had the opportunity to meet Elliott can do so this weekend at the Association of Health Care Journalists conference in Philadelphia, where he'll be on a panel, "Clinical trials: Intersection of ethical, practical and financial." Hint: If you don't want to hear what's broken, don't come.

Money, Marketing, and Ethics: Can They Work Together? (breast cancer)

Clinical practice guidelines as marketing tools -- Collier 183 (3): E141 -- Canadian Medical Association Journal

Blogger's Note: bias exist no matter the source, what does matter is the degree and ultimately the intent (ethics)
 ....................................................................................
"If the guidelines are funded by government or private donors, a bias toward recommending particular pharmaceuticals may not be present."